-
THE FDA HAS APPROVED THE FIRST NEW WEIGHT LOSS DRUG in more than a decade.
-
Clinical Briefs: Another Look at Bleeding Risk from Aspirin; Can Aspirin Prevent Recurrence of Thromboembolism?; A New Approach to Tinnitus
-
While regular exercise is beneficial to overall health, repeated long-term endurance exercise — such as marathons, ultramarathons, ironman triathlons, and long-distance bicycle racing — may cause myocardial scarring and increase the risk of serious arrythmias, coronary artery calcification, diastolic dysfunction, and large-artery wall stiffening.
-
People using oral bisphosphonates for the first time may be at a higher risk of developing ocular inflammatory adverse events such as scleritis and uveitis.
-
Cardiovascular disease (CVD) is a complex group of heart-related conditions that are the leading cause of death among Americans and Europeans.
-
Acupressure is a therapeutic intervention that has its roots in Traditional Chinese Medicine (TCM) and is based on the same meridian theory used in acupuncture. However, rather than using needles, acupoints are typically stimulated using pressure from fingers, hands, elbows or, in some cases, by devices.
-
A systematic review of 29 studies using vitamin C to help lower blood pressure showed a slightly positive effect, though of debatable clinical value. The study highlights the variable nature of existing data in this realm with regards to quality and methodology.
-
Two large, well-known, U.S. prospective cohort studies, the Nurses' Health Study and the Health Professionals Follow-up Study, evaluated both sugar-sweetened and diet (low-calorie, also called artificially sweetened) soda consumption over 20 years and found one or more daily servings to be associated with a significantly higher risk of stroke.
-
The first retinoid as a topical foam has been approved by the FDA for the treatment of acne. Tazarotene is a synthetic, third-generation, polyaromatic, prodrug that binds to the retinoic acid receptors. Tazarotene is available in both gel and cream formulations. The foam is marketed by Stiefel as Fabior™.
-
The lifetime risk of cardiovascular disease is strongly influenced by risk factor burden and may be similar across race and birth cohorts.
